• UBS analysts warn that rising use of GLP-1 weight-loss drugs may reduce restaurant sales, particularly for fast-food and less healthy chains.
  • Users are cutting calories, dining out less, and shifting to healthier options, prompting restaurants to adapt menus with smaller portions and healthier choices.
  • The trend could become a significant headwind for the industry, with potential long-term revenue implications.

A new headwind for restaurants

UBS has flagged growing adoption of GLP-1 weight-loss drugs as a potential drag on restaurant sales, according to a research note seen by Investing.com. The drugs, which suppress appetite and promote weight loss, are changing consumer behavior: users report eating smaller portions, skipping meals, and dining out less frequently. Fast-food chains and those with calorie-dense menus are seen as most vulnerable.

“We expect restaurants to increasingly adapt menus with smaller portions and healthier options,” the UBS analysts wrote, noting that the shift could pressure same-store sales and traffic. The bank’s analysis echoes recent surveys from BTIG and Circana, which found that a significant share of GLP-1 users are cutting back on restaurant visits and opting for lighter fare when they do go out.

Industry bracing for impact

The warning comes as the restaurant industry already faces inflation and cautious consumer spending. JPMorgan has projected potential annual sales losses of billions of dollars for the broader food-and-beverage sector if GLP-1 adoption continues to grow. While the immediate effect may be modest, UBS sees the trend as a structural shift that operators cannot ignore.

Some chains are already experimenting with menu changes. McDonald’s and other fast-food giants have introduced lighter options, but the challenge is greater for brands built on indulgence. “It’s a slow burn, but the direction is clear,” said one industry consultant. A spokesperson for UBS declined to comment beyond the note.

Correction: An earlier version of this article misstated the source of the survey data. The correct source is BTIG and Circana.